MZMarcin Zdzienicki

Marcin Zdzienicki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marcin Zdzienicki has a total of 229 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The value of ultrasound-guided core-needle biopsy in the diagnosis of retroperitoneal sarcomas

    by Jacek Skoczylas, Grzegorz Rosiak, Iwona Kalinowska, Konrad Zaborowski, Andrzej Pieńkowski, Marcin Zdzienicki, Piotr Jan Błoński, Paweł Michalak, Paweł Teterycz, Piotr Rutkowski

    Introduction Soft tissue sarcomas are a diverse group of tumours located in various regions of the body. A particularly challenging diagnostic localization is the retroperitoneal space, due to the difficulties in accessing this area for biopsy and the associated challenges in selecting the appropriate technique to obtain reliable histopathological material that determines further treatment. Material The analysis data from 177 consecutive patients who underwent surgical intervention for sarcomas of the retroperitoneal space in the Department of Soft Tissue, Bone and Melanoma Tumors between 2017 and 2023. Results A total of 177 patients were subjected to biopsy analysis. Tissue material was obtained from all patients through biopsy in order to confirm the diagnosis of retroperitoneal sarcoma. Thirty patients underwent an open biopsy, two patients underwent a core-needle biopsy under CT guidance, and 144 patients underwent an ultrasound-guided biopsy. The histological subtype changed in 40% of cases, while the grade of malignancy changed in 30% in final postoperative diagnosis. Complications after biopsy requiring surgery occurred in one case. Furthermore, there was no alteration in the diagnosis from malignant to benign lesion in the postoperative material. Conclusions Computed tomography (CT-) or ultrasound-guided core-needle biopsy is preferred and safe procedure to establish pathologic diagnosis in soft tissue tumors, however still open biopsy can be considered in selected cases. Core needle biopsy can establish a preoperative diagnosis and does not involve surgery or general anaesthesia. The open biopsy procedure should be considered a last resort, to be used only when a minimally invasive core-needle biopsy cannot be performed safely. Further research is required to determine the most suitable biopsy site from the tumour to minimise the variation in the degree of malignancy and subtype in the final diagnosis.

  • A real-life multicenter study on the treatment of locally advanced Merkel cell carcinoma

    by Piotr Rutkowski, Monika Dudzisz-Śledź, Pawel Sobczuk, Katarzyna Kozak, Tomasz Switaj, Hanna Kosela-Paterczyk, Anna Malgorzata Czarnecka, Slawomir Falkowski, Pawel Rogala, Tadeusz Morysinski, et al.

  • Prognostic and predictive factors for the outcomes of clear cell sarcoma (CCS) multidisciplinary treatment: The role of lymph node involvement.

    by Pawel Teterycz, Anna Malgorzata Czarnecka, Aleksandra Szmajdzinska, Magdalena Kalejta, Mateusz Spalek, Magdalena Rosinska, Jan Poleszczuk, Tomasz Switaj, Marcin Zdzienicki, Slawomir Falkowski, et al.

    E23554 Background: CCS is a rare aggressive sarcoma with melanocytic differentiation and specific genetic background of EWSR1/ATF1 or EWSR1/CREB1 translocations. It typically localizes in the tendons, fascia, and aponeuroses. The role of lymph node dissection (LND) remains to be elucidated in this sarcoma, although it was indicated to have a high rate of clinically occult regional lymph node (LN) metastases. Methods: 23 consecutive patients (pts) (15 women and 8 men) were referred, diagnosed and underwent multidisciplinary treatment in our Institute between 07/2000 and 12/2019. Kaplan-Meier estimator was used in survival analysis and univariate Cox proportional hazard model was used to investigate prognostic and predictive factors. Cases for whom local relapsed were not noted or those not known to be dead were censored at last visit. OS was compared for nodal involvement, including both: clinically detected and treated with therapeutic LND and microscopic metastases evaluated in sentinel LN biopsy (SLNB). Local relapse and radiotherapy were analyzed. Results: The median age at diagnosis was 32y (range:20-72). The median tumor size was 3.5cm (2-15cm). 15 pts underwent surgery of the primary tumor and 8 - resection of local relapse after non-complete resection outside the reference center. In 11 cases SNLB was performed, while in 7 – therapeutic LND. SLNB was positive in 2 (18%) cases and was followed by completion LND. For pts treated due to primary tumor, R0 resection was achieved in 12 cases and R1 in 3. After median follow-up of 65.6 months (m) (95% confidence interval, CI 55.3–NR) 11 (48%) pts are alive. Median OS was 59m (95%CI: 39-NR). Clinically detectable LN were correlated with shorter DFS (HR: 6.6, 95%CI: 1.5-28.8, p = 0.01). The number of involved LN also correlated with DFS (HR 1.7 per 1 LN; 95%CI:1.1-2.6, p = 0.009). No such correlations were found for OS. 5-year LRFS rate was 72.5% (95%CI: 53.8-97.7). 15 pts underwent neoadjuvant radiotherapy and for these pts 5-year LRFS rate was 75.0% (95%CI: 50.3-100). There was no statistical difference for LRFS if radiation therapy was not applied, which may be due to the number of pts. Conclusions: CCS is a highly aggressive sarcoma with poor prognosis. High quality surgery remains the gold standard for these pts, with the increasing role of SLNB and LND. Multimodal treatment should be considered in all cases. There is unmet need for new therapies for advanced CCS pts.


  • Efficacy and safety of hypofractionated preoperative radiotherapy in treatment of patient with primary locally advanced soft tissue sarcoma of limbs/trunk wall.

    by Hanna Kosela, Mateusz Spalek, Aneta Borkowska, Pawel Teterycz, Tadeusz Morysinski, Michal Wagrodzki, Tomasz Goryn, Marcin Zdzienicki, Piotr Rutkowski

    11555 Background: Soft tissue sarcomas (STS) are rare often malignant tumors. The primary treatment of most STS is radical resection with adjuvant radiotherapy. Our previous study showed that the use of preoperative hypofractionated radiotherapy is safe and efficient in the treatment of unselected group of patients with STS. Aim of this study was to assess the use of the treatment scheme in patients with primary STS treated in one institution. Methods: 311 patients (52% female) with primary locally advanced STS participated in this prospective trial conducted from 2010 till 2017. Median age was 55 years (range: 17-91). Median follow up is 57 months (95%CI 55-61). The most common subtypes were pleomorphic sarcoma, liposarcoma and synovial sarcoma. Median tumor size was 11cm. 258 patients (83%) had high grade tumors. The most common tumor localization were lower limbs (72%). 30% of patients received preoperative chemotherapy. For five consecutive days radiotherapy in 5 x 5Gy fraction was applied, with immediate (2-4 days) resection of the tumor. Results: In 260 patients (83.6%) clear surgical margins (R0) were obtained. 107 patients were dead at the time of the analysis.5-year overall survival is 63%. 156 (50%) had a recurrence of the disease. Local recurrence (LR) was found in 13.8% of the patients. Median time from surgery to LR was 14.7 months. In 56% of patients with LR another limb spearing radical surgery could be performed. Factors that had a significant adverse impact on LR were histological subtype (p = 0.017) and surgical margin status (p = 0.013). Factors that had a significant adverse impact on overall survival were tumor size (p < 0.0001), grade (p = 0.0047) and surgical margin status (p = 0.013). 96 patients (30.8%) had any kind of treatment toxicity, factor having negative impact on the toxicity was lower limb location of the tumor (p = 0.0012). 20 patients (6.4%) required surgery for treatment of the complications. 14.6% patients had prolonged healing of the wound ( > 1 month), 8.3% had wound dehiscence, 1.4% required prolonged punctures of the lymph fluid, 2.3% had severe fibrosis leading to contracture of limb, 11% patients prolonged edema of the operated limb. 0.9% of patients had a fracture of the treated limb. Conclusions: In this group, with a big percentage of patients with large, high grade STS use of hypofractionated preoperative radiotherapy was associated with similar local control when compared to published studies. The early toxicity is tolerable, with a small amount of late complications.

  • The Comparison of 8th and 7th Edition of AJCC Staging System in Melanomas at Locoregional Stage

    by Piotr Rutkowski, Iwona Lugowska, Hanna Kosela-Paterczyk, Marcin Zdzienicki, Tomasz Goryn, Pawel Teterycz

  • Open Access

    Functional outcome of surgical treatment of adults with extremity osteosarcoma after megaprosthetic reconstruction—single-center experience

    by Tomasz Goryń, Andrzej Pieńkowski, Bartłomiej Szostakowski, Marcin Zdzienicki, Iwona Ługowska, Piotr Rutkowski

    Background: Osteosarcoma is the most common primary malignant bone tumor in adults and is usually located in the long bones. Standard treatment consists of perioperative chemotherapy and radical surgical resection. Limb-sparing surgery using a variety of reconstructive techniques remains the gold standard. Methods: In our study, we retrospectively analyzed 90 adult patients operated at our institution between 2000 and 2017 for extremity osteosarcoma that underwent limb-sparing reconstruction with the megaprosthesis. Sixty-one patients underwent resection and reconstruction of the distal femur, 9 patients—proximal femur, 7 patients—proximal tibia, 5 patients—total femoral resection and reconstruction, 5 patients—proximal humeral resection, and 3 patients—other types of resection with endoprosthetic reconstruction. The median follow-up time was 41 months, median overall survival was 86 months (3–225 months), and progression-free survival was 81 months (1–86 months). Functional assessment was made on 48 out of 56 living patients, after endoprosthetic reconstruction. The assessment was made according to MSTS functional scale. Results: In 14 cases (15%), the endoprosthesis had to be explanted, or amputation was performed for local recurrence or septic complication. Due to a mechanical failure of the implant, we had to perform a revision in 5 patients (5%). Eighteen out of 74 patients with endoprosthesis died of the disease. The median MSTS score was 84% (53–100%), and the best result of 85% was achieved in patients after distal femoral resection with endoprosthetic reconstruction. Conclusion: Careful planning of the treatment of patients with extremity osteosarcoma that is performed at the referral centers gives the possibility of long-term survival with a good and excellent functional result.


  • Merkel cell carcinoma (MCC) – neuroendocrine skin cancer

    by Monika Dudzisz-Śledź, Marcin Zdzienicki, Piotr Rutkowski

    Merkel cell carcinoma (MCC) is a rarely occurring skin cancer of high malignancy. It develops, most probably, from the neuroendocrine cells (Merkel’s cells). The most frequent location of this cancer is the skin of the head and neck (44–48% of cases), and then in the skin of the upper limbs (about 19% of cases) and then the lower limbs (16–20% of cases). The aetiology of this cancer is unknown, yet some role in its pathogenesis is played by ultraviolet light and immunosuppression. The basis of therapy in cases with locoregional spread is surgical intervention, whilst in more advanced cases, an effective systemic treatment is possible with the use of molecularly targeted therapies. This paper presents the current treatment possibilities in patients with Merkel cell carcinoma. Merkel cell carcinoma (MCC) is a rarely occurring skin cancer of high malignancy. It develops, most probably, from the neuroendocrine cells (Merkel’s cells). The most frequent location of this cancer is the skin of the head and neck (44–48% of cases), and then in the skin of the upper limbs (about 19% of cases) and then the lower limbs (16–20% of cases). The aetiology of this cancer is unknown, yet some role in its pathogenesis is played by ultraviolet light and immunosuppression. The basis of therapy in cases with locoregional spread is surgical intervention, whilst in more advanced cases, an effective systemic treatment is possible with the use of molecularly targeted therapies. This paper presents the current treatment possibilities in patients with Merkel cell carcinoma.


  • Clinicopathological prognostic and predictive factors of malignant peripheral nerve sheath tumors (MPNST) survival and treatment efficacy.

    by Pawel Sobczuk, Pawel Teterycz, Marcin Zdzienicki, Marcin Napierala, Tadeusz Morysinski, Tomasz Switaj, Piotr Rutkowski, Anna Malgorzata Czarnecka

    E22537 Background: MPNST accounts for about 5% of soft tissue sarcomas. It is known to have high metastatic potential and poor prognosis, but reported long-term outcomes vary widely across published series. Our study aimed to determine factors affecting clinical outcome in a large cohort of patients (pts) with MPNSTs treated at reference sarcoma center. Methods: 289 consecutive pts (144 woman and 145 man) referred, diagnosed and treated between 03/1998 and 04/2018 were analyzed. Kaplan-Meier estimator and the log-rank test were used in survival analysis and multivariate Cox proportional hazards model was used to confirm the correlation. Results: Mean age at diagnosis was 50y (15-86). 39 (13.5%) pts were NF1 positive, 12 were primary diagnosed with metastatic disease. After median follow-up of 66.5 months (m) (95% confidence interval, CI 58.1 – 85.2) 151 pts continue treatment or follow-up. Median OS was 55.7m (39.3 - 148.9) in the whole group while 5y survival rate was 48.8% (CI: 42.8-55.7%). 37/167 pts with radical resection in reference center developed local recurrence, and 75/92 pts operated first in regional hospitals. Median DFS was 29.7m (CI: 16.1-58.3) in case of treatment in reference center and 4.1m (CI: 2.4-9.2) in case of regional hospital (p < 0.001).72 pts developed metastatic disease and were treated with chemotherapy. Median PFS on 1st line was 5.6m (CI: 3.3 - 8.1), There were no statistically significant differences in survival rates nor in response rates between doxorubicin- and ifosfamid-based regiments. Tumor size at diagnosis (HR:2.33, CI: 1.50-3.62), high grade (HR:3.31, CI:2.14-5.12) and R0 resection (HR:0.47, CI:0.30-0.72) were the strongest independent predictors of DFS and OS. (neo)adjuvant radiotherapy did not influenced LRFS in case of R0 resection but improved LRFS when complete resection was not feasible (HR: 0.22 CI: 0.08-0.58 p = 0.002). Conclusions: MPSNT is a highly aggressive tumor with poor prognosis. High quality surgery remains the mainstay of management for these patients, but multimodal treatment should be considered in majority of cases in MDT units. There is unmet need for new therapies in advanced/metastatic cases.

  • Malignant peripheral nerve sheath tumour (MPNST)

    by Anna M. Czarnecka, Paweł Sobczuk, Marcin Zdzienicki, Mateusz Spałek, Piotr Rutkowski

    MPNST is a malignant neoplasm of peripheral nerves, usually arising in connection with nerve trunks of the limbs and torso. It can develop de novo or on the basis of an already existing neurofibroma. Such tumours constitute about 5% of soft tissue sarcomas. In 90%, they occur in patients in the 2–5 decade of life. The main risk factor for this cancer is type 1 neurofibromatosis (von Recklinghausen disease). The radical surgical treatment — tumour excision, within the limits of healthy tissues (wide local excision), combined with adjuvant radiotherapy, is of primary importance in the treatment of MPNST. In cases of metastatic disease, palliative chemotherapy is used, using doxorubicin or doxorubicin with ifosfamide. Clinical improvement after chemotherapy is observed in approximately 25–30% of patients. Considering the development of molecular biology research of MPNST, one can hope for development of inhibitors that show greater effectiveness than typical chemotherapy in these patients in the near future. Currently, clinical trials with pembrolizumab, nivolumab in combination with ipilimumab, pexidartinib (KIT inhibitor, CSF1R and FLT3) in combination with sirolimus, sapanisertib (TORC 1/2 inhibitor) or LOXO-195 (inhibitor of neurotrophic tyrosine kinase inhibitors NTRK type 1, 2 and 3) are performed in MNSNT patients. MPNST is a malignant neoplasm of peripheral nerves, usually arising in connection with nerve trunks of the limbs and torso. It can develop de novo or on the basis of an already existing neurofibroma. Such tumours constitute about 5% of soft tissue sarcomas. In 90%, they occur in patients in the 2–5 decade of life. The main risk factor for this cancer is type 1 neurofibromatosis (von Recklinghausen disease). The radical surgical treatment — tumour excision, within the limits of healthy tissues (wide local excision), combined with adjuvant radiotherapy, is of primary importance in the treatment of MPNST. In cases of metastatic disease, palliative chemotherapy is used, using doxorubicin or doxorubicin with ifosfamide. Clinical improvement after chemotherapy is observed in approximately 25–30% of patients. Considering the development of molecular biology research of MPNST, one can hope for development of inhibitors that show greater effectiveness than typical chemotherapy in these patients in the near future. Currently, clinical trials with pembrolizumab, nivolumab in combination with ipilimumab, pexidartinib (KIT inhibitor, CSF1R and FLT3) in combination with sirolimus, sapanisertib (TORC 1/2 inhibitor) or LOXO-195 (inhibitor of neurotrophic tyrosine kinase inhibitors NTRK type 1, 2 and 3) are performed in MNSNT patients.


  • Open Access

    Long-term follow-up in adults with extremity osteosarcoma: comparison of different surgical procedures – single-center experience

    by Tomasz Goryń, Bartłomiej Szostakowski, Andrzej Pieńkowski, Marcin Zdzienicki, Iwona Ługowska, Piotr Rutkowski

    Introduction Osteosarcoma is the most common primary malignant bone tumor in adults and is usually located in long bones. Standard treatment consists of perioperative chemotherapy and radical surgical resection. In the case of the extremity location, the gold standard is limb-sparing surgery...